Molecular Profile Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS Q61H lung adenocarcinoma decreased response MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Binimetinib Preclinical - Cell culture Actionable In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61H mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710). 27422710
KRAS Q61H non-small cell lung carcinoma resistant PI3K Inhibitor (Pan) Pictilisib Preclinical Actionable In a preclinical study, a human non-small cell lung cancer cell line harboring KRAS Q61H (PMID: 19165201) were insensitive to pictilisib (GDC-0941) growth inhibition in culture (PMID: 22693356). 22693356 19165201
KRAS Q61H colorectal cancer predicted - resistant MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Panitumumab + Trametinib Case Reports/Case Series Actionable In a clinical case study, Vectibix (panitumumab) and Mekinist (trametinib) combination treatment inhibited growth of liver metastasis harboring MAP2K1 K57T in a patient with colorectal cancer, but the disease progressed due to the outgrowth of a clone of metastatic tumor harboring KRAS Q61H (PMID: 26644315). 26644315
KRAS Q61H lung cancer predicted - resistant RMC-4550 Preclinical - Cell culture Actionable In a preclinical study, RMC-4550 did not inhibit growth of lung cancer cell lines harboring KRAS Q61H in 3D culture (PMID: 30104724). 30104724
KRAS Q61H non-small cell lung carcinoma sensitive PI3K Inhibitor (Pan) CUDC-907 Preclinical Actionable In a preclinical study, CUDC-907 inhibited growth and repressed RAF-MEK-MAPK signaling as indicated by reduced phosphorylation of Craf, Mek, and Mapk in a human non-small cell lung cancer cell line harboring KRAS Q61H in culture (PMID: 19165201, PMID: 22693356). 22693356 19165201
KRAS Q61H ovarian carcinoma predicted - sensitive Bevacizumab + Sorafenib Case Reports/Case Series Actionable In a Phase I trial, a patient with ovarian carcinoma harboring KRAS Q61H demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in 62% tumor regression (PMID: 25363205). 25363205
KRAS Q61H non-small cell lung carcinoma sensitive AZD4785 AZD4785 Preclinical - Cell culture Actionable In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cell lines harboring KRAS Q61H (PMID: 28615361). 28615361
KRAS Q61H lung adenocarcinoma decreased response MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Selumetinib Preclinical - Cell culture Actionable In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61H mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710). 27422710
Clinical Trial Phase Therapies Title Recruitment Status